What is Raymond James’ Forecast for TSE:ONC FY2024 Earnings?

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at Raymond James lowered their FY2024 EPS estimates for shares of Oncolytics Biotech in a research note issued on Tuesday, November 12th. Raymond James analyst R. Sarugaser now anticipates that the company will post earnings per share of ($0.44) for the year, down from their previous forecast of ($0.38). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Trading Down 4.1 %

TSE ONC opened at C$1.41 on Friday. Oncolytics Biotech has a one year low of C$1.15 and a one year high of C$2.32. The company has a 50-day simple moving average of C$1.49 and a 200-day simple moving average of C$1.45. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The firm has a market capitalization of C$108.37 million, a PE ratio of -3.71 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.